We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety of Intramuscular Injection of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00919958
First Posted: June 12, 2009
Last Update Posted: June 19, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Pluristem Ltd.
  Purpose
The The purpose of this study is to determine the safety of PLX-PAD single dose, Intra-muscular injection for the treatment of CLI patients.

Condition Intervention Phase
Peripheral Artery Disease Peripheral Vascular Disease Critical Limb Ischemia Biological: PLX-PAD IM injection Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of Intramuscular (IM) Injection of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia. PLX-PAD Are Mesenchymal-like Stromal Cells Derived From a Full Term Placenta. These Placental Adherent Stromal Cells (ASCs) Are Expanded in the Company's Proprietary PluriXTM 3D Bioreactor System. PLX Cells Are Immune Privileged and Possess Immunomodulatory Properties.

Further study details as provided by Pluristem Ltd.:

Primary Outcome Measures:
  • Adverse events, Safety laboratory values and ECG findings [ Time Frame: 3 months ]
  • Immunological reaction [ Time Frame: 1 month ]

Secondary Outcome Measures:
  • Tumorigenesis [ Time Frame: 24 months ]

Enrollment: 15
Study Start Date: June 2009
Study Completion Date: June 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PLX-PAD low dose Biological: PLX-PAD IM injection
Single treatment; multiple injections
Experimental: PLX-PAD intermediate dose Biological: PLX-PAD IM injection
Single treatment; multiple injections
Experimental: PLX-PAD high dose Biological: PLX-PAD IM injection
Single treatment; multiple injections

Detailed Description:
PLX-PAD are mesenchymal-like stromal cells derived from a full term placenta, termed PLX-PAD, and intended for the treatment of Critical Limb Ischemia
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 81 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Diagnosis of critical limb ischemia defined as persistent, recurring ischemic rest pain for at least two (2) weeks, and/or ulceration or gangrene of the foot or toe, with ABI < 0.4 or/and TBI < 0.4 or transcutaneous partial pressure of oxygen ≤ 30 mmHg pO2 at the foot.
  2. Rutherford category 4-5
  3. No acceptable options for re-vascularisation as confirmed by angiographic imaging results or by color flow duplex ultrasound obtained within 6 months prior screening visit and signed approval of vascular surgeon.
  4. In the opinion of the investigator, major amputation is not anticipated over a period of three (3) months.

Exclusion Criteria:

  1. Uncontrolled hypertension (defined as diastolic blood pressure > 110 mmHg or systolic blood pressure > 180 mmHg during screening).
  2. Poorly controlled diabetes mellitus (HbA1c > 9%)
  3. Wounds with severity greater than Grade 2 on the Wagner Scale
  4. Life-threatening ventricular arrhythmia - except if an ICD is implanted - or unstable angina pectoris - characterized by increasingly frequent episodes with modest exertion or at rest, worsening severity, and prolonged
  5. ST segment elevation myocardial infarction and/or TIA/CVA within six (6) months prior to enrollment. Patients with severe congestive heart failure (i.e. NYHA Stage IV)
  6. In the opinion of the investigator, the patient is unsuitable for cellular therapy.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00919958


Locations
Germany
Franziskus-Krankenhaus
Berlin, Germany
Sponsors and Collaborators
Pluristem Ltd.
Investigators
Principal Investigator: Prof. Carsten Tschöpe, MD Charite University, Berlin, Germany
  More Information

Responsible Party: Pluristem Ltd.
ClinicalTrials.gov Identifier: NCT00919958     History of Changes
Other Study ID Numbers: PLX-PAD 1202-1
First Submitted: June 10, 2009
First Posted: June 12, 2009
Last Update Posted: June 19, 2012
Last Verified: June 2012

Keywords provided by Pluristem Ltd.:
Peripheral Artery Disease
Peripheral Vascular Disease
Critical limb ischemia

Additional relevant MeSH terms:
Ischemia
Vascular Diseases
Peripheral Arterial Disease
Peripheral Vascular Diseases
Pathologic Processes
Cardiovascular Diseases
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases